Antineoplastic AgentsProstateAntineoplastic Agents, PhytogenicLeukemia P388Amaryllidaceae AlkaloidsNarcissusEllipticinesBibenzylsDrug Screening Assays, AntitumorDoxorubicinAntibiotics, AntineoplasticCell Line, TumorProstatic NeoplasmsThiadiazinesBryostatinsTumor Cells, CulturedAntineoplastic Agents, AlkylatingNeoplasmsApoptosisAncitabineProstate-Specific AntigenGalliumDepsipeptidesPaclitaxelCisplatinDrug SynergismCell Survival6-MercaptopurineEpothilonesAminoacridinesMolecular StructureSarcoma 180LactonesXenograft Model Antitumor AssaysDose-Response Relationship, DrugCell DivisionProstatic HyperplasiaLeukemia L1210Mice, NudeAntimetabolites, AntineoplasticCell ProliferationDaunorubicinFluorouracilDrug Resistance, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsAndrogensReceptors, AndrogenBleomycinEtoposideProdrugsDrug Evaluation, PreclinicalDrug EvaluationCell CycleNeoplasm TransplantationProstatectomyNeoplasms, ExperimentalAndrogen AntagonistsDrug ResistanceStilbenesEnzyme InhibitorsMacrolidesCamptothecinMethotrexateTime FactorsLung NeoplasmsTransurethral Resection of ProstateDrug Administration ScheduleHL-60 CellsRNA, MessengerBreast NeoplasmsOrchiectomyTaxoidsGene Expression Regulation, NeoplasticProstatic Intraepithelial NeoplasiaAdenocarcinomaVincristineIsoquinolinesClinical Trials as TopicBiotransformationDrug InteractionsCell LineDNA DamageStereoisomerismCaspasesCyclophosphamideOvarian NeoplasmsKineticsColonic NeoplasmsLeukemiaNeoplasms, Hormone-DependentTreatment OutcomeDNATumor Markers, BiologicalStructure-Activity RelationshipBone NeoplasmsCells, CulturedProstatic DiseasesReactive Oxygen SpeciesDihydrotestosteroneDisease Progression